Previous Article | Next Article 
Journal of Virology, November 1998, p. 8943-8951, Vol. 72, No. 11
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Development of a Neutralizing Antibody Response
during Acute Primary Human Immunodeficiency Virus Type 1 Infection and
the Emergence of Antigenic Variants
J.
Lewis,1
P.
Balfe,2,*
C.
Arnold,3
S.
Kaye,2
R. S.
Tedder,2 and
J.
A.
McKeating1
School of Animal and Microbial Sciences,
University of Reading, Reading RG6 2AJ,1
Department of Virology, The Windeyer Institute of Medical
Sciences, UCLMS, London W1P 6DB,2 and
Virus Reference Laboratory, CPHL, Colindale, London NW9
5HT,3 United Kingdom
Received 8 May 1998/Accepted 4 August 1998
We monitored the primary humoral response to human immunodeficiency
virus type 1 infection and showed that, in addition to antibodies to
p24 and gp41, antigens which form the basis of most diagnostic assays,
the response included a significant antibody response directed to the
gp120 region of the infecting viral quasispecies. When tested in a
recombinant virus neutralization assay, these antibodies were capable
of inhibiting viral growth. We found the primary viral quasispecies to
solely utilize the CCR-5 chemokine receptor; however, recombinant
viruses differed in their cytopathology and in their sensitivity to
-chemokine inhibition of viral growth. Sequence analysis of the
gp120 open reading frames showed that amino acid changes in the C1
(D
G at position 62) and C4 (V
A at position 430) regions accounted
for the phenotypic differences. These data demonstrate that early in
infection, polymorphism exists in envelope glycoprotein
coreceptor interactions and imply that therapeutic strategies targeted
at this step in the viral life cycle may lead to rapid resistance.
*
Corresponding author. Mailing address: Department of
Virology, The Windeyer Institute of Medical Sciences, UCLMS, 46 Cleveland St., London W1P 6DB, United Kingdom. Phone: 44 171 504 9490. Fax: 44 171 580 5896. E-mail: p.balfe{at}ucl.ac.uk.
Journal of Virology, November 1998, p. 8943-8951, Vol. 72, No. 11
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Jayaraman, P., Zhu, T., Misher, L., Mohan, D., Kuller, L., Polacino, P., Richardson, B. A., Bielefeldt-Ohmann, H., Anderson, D., Hu, S.-L., Haigwood, N. L.
(2007). Evidence for Persistent, Occult Infection in Neonatal Macaques following Perinatal Transmission of Simian-Human Immunodeficiency Virus SF162P3. J. Virol.
81: 822-834
[Abstract]
[Full Text]
-
Beaumont, T., Quakkelaar, E., van Nuenen, A., Pantophlet, R., Schuitemaker, H.
(2004). Increased Sensitivity to CD4 Binding Site-Directed Neutralization following In Vitro Propagation on Primary Lymphocytes of a Neutralization-Resistant Human Immunodeficiency Virus IIIB Strain Isolated from an Accidentally Infected Laboratory Worker. J. Virol.
78: 5651-5657
[Abstract]
[Full Text]
-
Polonis, V. R., Souza, M. S. d., Darden, J. M., Chantakulkij, S., Chuenchitra, T., Nitayaphan, S., Brown, A. E., Robb, M. L., Birx, D. L.
(2003). Human Immunodeficiency Virus Type 1 Primary Isolate Neutralization Resistance Is Associated with the Syncytium-Inducing Phenotype and Lower CD4 Cell Counts in Subtype CRF01_AE-Infected Patients. J. Virol.
77: 8570-8576
[Abstract]
[Full Text]
-
Hsu, M., Harouse, J. M., Gettie, A., Buckner, C., Blanchard, J., Cheng-Mayer, C.
(2002). Increased Mucosal Transmission but Not Enhanced Pathogenicity of the CCR5-Tropic, Simian AIDS-Inducing Simian/Human Immunodeficiency Virus SHIVSF162P3 Maps to Envelope gp120. J. Virol.
77: 989-998
[Abstract]
[Full Text]
-
Jeffs, S. A., Shotton, C., Balfe, P., McKeating, J. A.
(2002). Truncated gp120 envelope glycoprotein of human immunodeficiency virus 1 elicits a broadly reactive neutralizing immune response. J. Gen. Virol.
83: 2723-2732
[Abstract]
[Full Text]
-
Hammond, A. L., Lewis, J., May, J., Albert, J., Balfe, P., McKeating, J. A.
(2001). Antigenic Variation within the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120: Effects on Chemokine Receptor Utilization. J. Virol.
75: 5593-5603
[Abstract]
[Full Text]
-
Beaumont, T., van Nuenen, A., Broersen, S., Blattner, W. A., Lukashov, V. V., Schuitemaker, H.
(2001). Reversal of Human Immunodeficiency Virus Type 1 IIIB to a Neutralization-Resistant Phenotype in an Accidentally Infected Laboratory Worker with a Progressive Clinical Course. J. Virol.
75: 2246-2252
[Abstract]
[Full Text]
-
Beaumont, T., Broersen, S., van Nuenen, A., Huisman, H. G., de Roda Husman, A.-M., Heeney, J. L., Schuitemaker, H.
(2000). Increased Neutralization Sensitivity and Reduced Replicative Capacity of Human Immunodeficiency Virus Type 1 after Short-Term In Vivo or In Vitro Passage through Chimpanzees. J. Virol.
74: 7699-7707
[Abstract]
[Full Text]
-
Flint, M., Thomas, J. M., Maidens, C. M., Shotton, C., Levy, S., Barclay, W. S., McKeating, J. A.
(1999). Functional Analysis of Cell Surface-Expressed Hepatitis C Virus E2 Glycoprotein. J. Virol.
73: 6782-6790
[Abstract]
[Full Text]
-
Scala, G., Chen, X., Liu, W., Telles, J. N., Cohen, O. J., Vaccarezza, M., Igarashi, T., Fauci, A. S.
(1999). Selection of HIV-Specific Immunogenic Epitopes by Screening Random Peptide Libraries with HIV-1-Positive Sera. J. Immunol.
162: 6155-6161
[Abstract]
[Full Text]